ABPI announces new President

John Kearney takes over from Jonathan Emms on 24 April

The UK's Association of the British Pharmaceutical Industry (ABPI) has appointed John Kearney as President of the Association. He will take up office on 24 April replacing Jonathan Emms who is stepping down following a promotion within Pfizer which sees him relocating to the US.

Kearney, General Manager UK and Ireland at Amgen, has 35 years of experience in the pharmaceutical industry. He held UK and international roles at GlaxoSmithKline and international roles at Pfizer before joining Amgen in 2007. An economics graduate, Kearney has been on the Board of the ABPI since 2008 where he has worked on a number of key initiatives including leading the Association’s pricing team in negotiations with the Department of Health to secure the 2014 Pharmaceutical Price Regulation Scheme (PPRS).

Emms has been promoted to Global Marketing Lead within the Global Established Pharmaceutical Business, based in New York. He will step down as ABPI President at the Association’s Annual General Meeting on 23 April.

You may also like

Media

Brexit White Paper - five key things for medicines

The ABPI, which represents innovative research-based biopharmaceutical companies in the UK, highlights five key points from the government's latest withdrawal plan
Media

Embracing new innovation in the face of Brexit

Dr Paul Catchpole commented at the NICE Annual Conference that adopting innovations will help bring investment into the UK and crucially help get more NHS patients onto ground breaking clinical trials programmes
Media

Life Sciences sector responds to report on the impact of Brexit

The Business, Energy and Indsutrial Strategy (BEIS) Committee report calls on the Government to secure a post-Brexit deal to protect patients and the UK's pharmaceutical industry
Media

New UK-wide agreement to speed up clinical trials and medicines research

Life Science leaders from across the UK have welcomed a new agreement that will make it easier for life-changing medicines and vaccines research and development to take place across different parts of the UK
Media

The pharma industry's response to PM’s latest Brexit speech

The Association of the British Pharmaceutical Industry (ABPI) – representing global pharmaceutical businesses in the UK including GSK, AstraZeneca, Pfizer and Roche – has responded to the ‘Road to Brexit’ speech by Prime Minister Theresa May
Media

Life Science Industry Coalition position paper released

The associations representing the European and British life science industry (AESGP, ABPI, BIA, BGMA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have launched a joint policy document on the potential impact of the UK’s exit from the EU
Media

Safeguarding public health must be number one priority

To coincide with the House of Commons Health Select Committee on <i>Brexit: the regulation of medicines, medical devices and substances of human origin</i>, the Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) have published new research on the public health implications of Brexit
Subscribe now